Fidelity Investments’s Oramed Pharmaceuticals ORMP Stock Holding History

Fidelity Investments’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$332	Sell	69 -131	-66%	-$521	﹤0.01%	5338
2026 Q1	$680	Sell	200 -300	-60%	-$1.02K	﹤0.01%	5134
2025 Q4	$1.43K	Hold	500	–	–	﹤0.01%	5062
2025 Q3	$1.32K	Buy	+500	New	+$1.1K	﹤0.01%	4987
2025 Q1	–	Sell	-1,700	Closed	-$4.11K	–	5586
2024 Q4	$4.11K	Buy	1,700 +200	+13%	+$475	﹤0.01%	4703
2024 Q3	$3.66K	Buy	+1,500	New	+$3.66K	﹤0.01%	4686
2024 Q1	–	Sell	-900	Closed	-$2.08K	–	5607
2023 Q4	$2.08K	Hold	900	–	–	﹤0.01%	4641
2023 Q3	$2.35K	Buy	+900	New	+$2.83K	﹤0.01%	4505
2023 Q2	–	Sell	-1,400	Closed	-$3.05K	–	5536
2023 Q1	$3.05K	Sell	1,400 -36,286	-96%	-$115K	﹤0.01%	4518
2022 Q4	$453K	Hold	37,686	–	–	﹤0.01%	2747
2022 Q3	$244K	Sell	37,686 -46,171	-55%	-$374K	﹤0.01%	2998
2022 Q2	$384K	Buy	83,857 +35,497	+73%	+$190K	﹤0.01%	2928
2022 Q1	$418K	Buy	+48,360	New	+$495K	﹤0.01%	3044

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments's ORMP Position: Q2 2026 in Review

Fidelity Investments reduced its Oramed Pharmaceuticals (ORMP) stake by 66% in Q2 2026, selling an estimated $521 and leaving 69 shares worth $332. The position accounts for ﹤0.01% of the portfolio, ranked #5338.

Fidelity Investments first reported a position in ORMP in Q1 2022 and has held it in 13 quarters since. The position peaked at $453K in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Fidelity Investments held 69 shares of Oramed Pharmaceuticals worth $332 as of Q2 2026.
Fidelity Investments sold 131 Oramed Pharmaceuticals shares in Q2 2026, an estimated $521.
Oramed Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5338 holding.
Fidelity Investments first reported a position in Oramed Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
Fidelity Investments's Oramed Pharmaceuticals position peaked at $453K in Q4 2022.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.